Vicus Therapeutics Overview
- Founded
-
2005
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Out of Business
Vicus Therapeutics General Information
Description
Provider of cancer treatment therapies intended to bring breakthrough immunotherapies to patients with cancer. The company's services mainly focus on offering a drug product that is controlled-release formulation of propranolol, a non-selective β-blocker, and etodolac, a COX-2 selective inhibitor, for combination with PD-1 inhibitors, enabling patients to get affordable access to lung cancer treatment therapies for advanced stage.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 55 Madison Avenue
- Suite 400
- Morristown, NJ 07960
- United States
+1 (973) 000-0000
Vicus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Feb-2019 | 00.000 | Completed | Out of Business | ||
| 4. Angel (individual) | 12-Aug-2010 | 00000 | 00.000 | Completed | Startup | |
| 3. Angel (individual) | 09-Jul-2009 | 00000 | 00.000 | Completed | Startup | |
| 2. Angel (individual) | 06-Aug-2008 | $800K | $1.6M | Completed | Startup | |
| 1. Angel (individual) | 27-Jul-2007 | $800K | $800K | Completed | Startup |
Vicus Therapeutics Patents
Vicus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9889120-B2 | Combination drug therapies for cancer and methods of making and using them | Active | 14-Jan-2016 | 0000000000 | 00 |
| US-20180169067-A1 | Combination drug therapies for cancer and methods of making and using them | Abandoned | 14-Jan-2016 | 0000000000 | 0 |
| US-20170202806-A1 | Combination drug therapies for cancer and methods of making and using them | Granted | 14-Jan-2016 | 0000000000 | |
| US-20170196901-A1 | Combination drug therapies for cancer and methods of making and using them | Abandoned | 13-Jan-2016 | 00000000000 | |
| US-20180369452-A1 | Combination compositions | Granted | 06-Jan-2016 | A61L27/50 |
Vicus Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
